Needham Reiterates Buy on Biogen, Maintains $270 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Biogen (NASDAQ:BIIB) and maintained a price target of $270.
October 31, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Biogen and maintained a price target of $270, indicating confidence in the company's stock performance.
The reiteration of a Buy rating and maintenance of a $270 price target by Needham suggests positive sentiment and confidence in Biogen's stock performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100